Trial-Results center  
Clinical trial results database Feedback    Home


Related trials

APPRAISE-1 (10mg od), 2009 - apixaban vs placebo

SEPIA-ACS1 TIMI 42, 2009 - otamixaban vs unfractioned heparin

PLATO, 2009 - ticagrelor + aspirin vs clopidogrel + aspirin

ATLAS ACS-TIMI 46, 2009 - rivaroxaban vs placebo

APPRAISE-1 (2.5 mg bid), 2009 - apixaban vs placebo

DISPERSE-2 (90mg), 2007 - ticagrelor + aspirin vs clopidogrel + aspirin

INTERACT, 2006 - enoxaparin vs UFH (on top of aspirin)

OASIS 5, 2006 - fondaparinux vs enoxaparin

PROTECT-TIMI 30, 2006 - Bivalirudin vs eptifibatide + heparin

SYNERGY, 2005 - enoxaparin vs UFH (on top of aspirin)

EVET, 2005 - enoxaparin vs tinzaparin

LoWASA, 2004 - warfarin vs control (on top of aspirin)

PENTUA, 2004 - fondaparinux vs enoxaparin

Zibaeenezhad, 2004 - warfarin vs control (on top of aspirin)

APRICOT-2, 2002 - warfarin vs control (on top of aspirin)

ASPECT-2 (coumadin+asp vs asp), 2002 - coumadin vs control (on top of aspirin)

WARIS, 2002 - warfarin vs control (on top of aspirin)

ASPECT-2 (coumadin vs aspirin), 2002 - coumadin vs aspirin

CHAMP, 2002 - warfarin vs control (on top of aspirin)

OASIS-2 Warfarin Substudy, 2001 - warfarin vs control (on top of aspirin)

CURE, 2001 - clopidogrel + aspirin vs aspirin

Huyhn, 2001 - warfarin vs placebo (on top of aspirin)

TIM, 2000 - triflusal vs aspirine

HIT-4, 1999 - Hirudin vs heparin

Klootwijk, 1999 - Efegatran vs heparin



See also:

  • All acute coronary syndrome clinical trials
  • All clinical trials of antithrombotics
  • All clinical trials of aspirin
    		•  

    RISC study, 1990

    Treatments

    Studied treatment Aspirin 75mg/d
    Control treatment placebo
    Remarks half of the patients received heparin in a 2x2 factorial design

    Patients

    Patients men with unstable coronary artery disease (unstable angina or non-Q wave myocardial infarction

    Method and design

    Randomized effectives 474 / 471 (studied vs. control)
    Design Factorial plan
    Blinding double blind
    Follow-up duration 12m
    Number of centre 8
    Geographic area Sweden


    Results

    Endpoint Studied treat.
    n/N     Control treat.
    n/N     Graph RR [95% CI]

    Non fatal MI

    36 / 474
         69 / 471
         0,52 [0,35;0,76]

    Vascular death

    9 / 474
         16 / 471
         0,56 [0,25;1,25]

    Non vascular death

    2 / 474
         2 / 471
         classic 0,99 [0,14;7,03]

    Non fatal stroke

    0 / 474
         0 / 471
         classic 0,99 [0,00;253,64]

    Vascular events

    45 / 474
         85 / 471
         0,53 [0,38;0,74]

    Major bleeding

    0 / 474
         0 / 471
         classic 0,99 [0,00;253,64]     0 2 1.0

    Relative risks
    Endpoint Events (%) Relative Risk 95% CI Endpoint definition
    in the trial    		 Ref
    Studied treat. Control treat.
    Non fatal MI 36 / 474 (7,6%) 69 / 471 (14,6%) 0,52 [0,35;0,76]    
    Vascular death 9 / 474 (1,9%) 16 / 471 (3,4%) 0,56 [0,25;1,25]    
    Non vascular death 2 / 474 (0,4%) 2 / 471 (0,4%) 0,99 [0,14;7,03]    
    Non fatal stroke 0 / 474 (0,1%) 0 / 471 (0,1%) 0,99 [0,02;49,98]    
    Vascular events 45 / 474 (9,5%) 85 / 471 (18,0%) 0,53 [0,38;0,74]    
    Major bleeding 0 / 474 (0,1%) 0 / 471 (0,1%) 0,99 [0,02;49,98]    
    The primary endpoint (if exists) appears in blod characters
    Reference(s) used for data extraction:
  • 0:

    • Endpoint studied treat. control treat. mean diff

    Absolute risk reduction
    Endpoint Events rate Absolute risk
    reduction (ARR)
    Studied treat. Control treat.
    Non fatal MI 7,59% 14,65% -70,5‰
    Vascular death 1,90% 3,40% -15,0‰
    Non vascular death 4,22‰ 4,25‰ -0,0‰
    Vascular events 9,49% 18,05% -85,5‰


    Reference(s)

    Trials register # NA
    • . Risk of myocardial infarction and death during treatment with low dose aspirin and intravenous heparin in men with unstable coronary artery disease. The RISC Group.. Lancet 1990;336:827-30
      Pubmed | Hubmed | Fulltext
    • Wallentin LC. Aspirin (75 mg/day) after an episode of unstable coronary artery disease: long-term effects on the risk for myocardial infarction, occurrence of severe angina and the need for revascularization. Research Group on Instability in Coronary Artery Disease in Southeast Sweden.. J Am Coll Cardiol 1991;18:1587-93
      Pubmed | Hubmed | Fulltext

    (c) 2004-2010 TrialResults-center - All Rights Reserved

    Tweet this  |  notify a friend